Pascal Dabel, MD
Nephrology · Mission Hills, CANPI 1033306592
Payments from drug & device makers
Across 315 payments — averaging $3773.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$399K
- GSK$317K
- Cleerly, Inc.$120K
- Travere Therapeutics, Inc.$96K
- Vertex$78K
- Pfizer$71K
- plus $108K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 58 | $398,837 |
| GSK | 41 | $316,632 |
| Cleerly, Inc. | 10 | $120,229 |
| Travere Therapeutics, Inc. | 37 | $96,154 |
| Vertex | 2 | $77,627 |
| Pfizer | 12 | $70,721 |
| Novo Nordisk AS | 3 | $68,682 |
| Aurinia Pharma U.S., Inc. | 22 | $25,255 |
| Biogen | 1 | $11,448 |
| AstraZeneca(2 entities) | 50 | $1,051 |
| Otsuka America Pharmaceutical, Inc. | 14 | $385 |
| Vifor Pharma, Inc. | 17 | $362 |
| Novartis | 8 | $185 |
| Akebia Therapeutics Inc | 7 | $158 |
| Veloxis Pharmaceuticals, Inc. | 2 | $101 |
| Henry Schein, Inc. | 2 | $88 |
| OPKO Pharmaceuticals, LLC | 4 | $88 |
| Fresenius USA Marketing, Inc. | 4 | $77 |
| Boehringer Ingelheim | 3 | $71 |
| Calliditas Therapeutics US Inc. | 3 | $71 |
| Nxstage Medical, Inc. | 1 | $45 |
| Sanofi | 3 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Lilly USA, LLC | 1 | $32 |
| Mallinckrodt Enterprises LLC | 1 | $31 |
| Bayer | 1 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Ardelyx, Inc. | 1 | $26 |
| Rockwell Medical, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
How this compares
$1,188,592 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Mission Hills
- Jehad HaggiagiMission Hills$3.6M
- Parag ShahMission Hills$1.9M
- Omaran AbdeenMission Hills$587K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.